drugset / Trial / NCT06711705
Elranatamab in Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the efficacy of elranatamab alone in patients with relapsed and/or refractory Multiple myeloma who has previously received 1 to 3 combinations of treatment.
Timeline
- Start
- 2024-12-18
- Primary completion
- 2029-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elranatamab | Monoclonal antibody | — | Subcutaneous |